Funding News Edition: June 19, 2019 See more articles in this edition
Question: Can you identify, develop, test, evaluate, and/or refine strategies to disseminate and implement evidence-based practices into public health, clinical practice, and community settings?
If so, you may be interested in these reissued multi-institute funding opportunity announcements (FOAs):
- Dissemination and Implementation Research in Health (R01, Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R21, Clinical Trial Optional)
Both FOAs support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to adopting, adapting, integrating, scaling-up, and sustaining evidence-based interventions, tools, policies, and guidelines.
Given the FOAs’ titles you might wonder, “What are dissemination research and implementation research?” They are defined as follows.
The former is the scientific study of targeted distribution of information and intervention materials to a specific public health or clinical practice audience. The intent: to understand how best to communicate and integrate knowledge and the associated evidence-based interventions.
The latter is the scientific study of using strategies to adopt and integrate evidence-based health interventions into clinical and community settings to improve individual outcomes and benefit population health.
Areas of Research Interest
Research topics may include the examples below. For others, see the FOAs.
- Studies of:
- Strategies to implement health promotion, prevention, screening, early detection, and diagnostic interventions, as well as effective treatments, clinical procedures or guidelines into existing care systems
- Implementing multiple evidence-based practices within community or clinical settings to meet the needs of complex patients and diverse systems of care
- Adapting evidence-based practices in the context of implementation
- Studies on reducing or stopping ("de-implementing") the use of clinical and community practices that are ineffective, unproven, low-value, or harmful
- Developing and strengthening tools and techniques for conducting rapid yet rigorous qualitative data collection and analysis
Note that all applications should be within the scope of at least one participating institute or center’s mission. NIAID’s scientific interests are stated in the FOA under Section I. Funding Opportunity Description:
Applicants applying to NIAID should identify partnerships with relevant policy and/or program leaders with a stated commitment to evaluate and incorporate changes which are proven to be both successful and cost-effective. Ideally, research teams will include local experts from an implementing organization and meaningfully incorporate input from community members.
NIAID will not accept clinical trials using new drugs or diagnostic tools, or using existing drugs/tools for new purposes in response to this FOA. However, trial methodology to assess the impact of new strategies for disseminating and/or implementing accepted/validated interventions for prevention or treatment will be allowed.
Applicants seeking funding for clinical trials should refer to Investigator-Initiated Clinical Trial Resources.
A Word About the R21 Opportunity
Applications submitted to the R21 FOA should be exploratory and novel, breaking new ground, or extending previous discoveries toward new directions or applications. Proposed projects should be distinct from those supported through the traditional R01 activity code. For example, long-term projects or projects designed to increase knowledge in a well-established area will not be considered for R21 awards.
Budget and Other Details
|R01 FOA||R21 FOA|
Not limited; must reflect actual needs of proposed project
Not to exceed $275,000 in direct costs for two-year project period
|Maximum Project Period||
For complete information, read the FOAs linked above. If you have questions about either, direct them to Melanie Bacon, NIAID’s scientific/research contact.